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Background: Medication-overuse headache (MOH) is a common problem in primary care. Brief intervention (BI) has
successfully been used for detoxification from overuse of alcohol and drugs. The aim of this pilot study was to
develop and test methodology, acceptability and logistics for a BI for MOH in primary care.
Findings: Observational feasibility study of an intervention in a Norwegian general practice population.
Six general practitioners (GPs) were recruited. A screening questionnaire for MOH was sent to all 18–50 year old
patients on these GPs` list. GPs were taught BI, which was applied to MOH patients as follows: Severity of
dependence scale (SDS) scores were collected and individual feedback was given of the relationship between the
SDS, medication overuse and headache. Finally, advice to reduce medication was given. Patients were invited to a
headache interview three months after the BI. Main outcomes were feedback from GPs/patients about the
feasibility and logistics of the study design, screening/recruitment process, BI and headache interviews. Efficacy and
patient-related outcomes were not focused. The patients reported a high degree of acceptability of the methodology.
The GPs reported the BI to be feasible to implement within a busy practice and to represent a new and improved
instrument for communication with MOH patients. The BI requires further testing in a randomised controlled trial (RCT)
in order to provide evidence of efficacy.
Conclusion: This feasibility study will be used to improve the BI for MOH and the design of a cluster-RCT.
Trial registration: ClinicalTrials.gov: NCT01078012 (Initially registered as controlled efficacy trial but changed to
observational study).
Keywords: Chronic headache, Medication-overuse headache, Migraine, Brief intervention, General practice, Severity of
dependence scale, Feasibility study, Pilot studyFindings
Background
Headache is a frequent symptom in primary care at-
tendees, accounting for 4% of the consultations in the
UK [1]. Headache prescription medications only partly
account for the total medication use for headache since
most patients buy over-the-counter (OTC) drugs [2-4].
Between two and five percent of the world’s population
report chronic headache [5-7], and approximately 75%
have been in contact with their GP [2,3]. Medication-
overuse headache (MOH) is a major cause of chronic* Correspondence: e.s.kristoffersen@medisin.uio.no
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distribution, and reproduction in any mediumheadache with prevalence in the general population of
1–1.5% [4,6,8-10], and is probably the most costly head-
ache disorder [11]. By definition, MOH is chronic head-
ache (≥15 days/month) with frequent medication use
(Table 1) [12-15].
There is no consensus on the management of MOH
and an obvious need for evidence-based and cost-effective
management strategies [10,16,17]. However, detoxification
is generally accepted as the avenue to employ [18], since
withdrawal of the overused medication(s) leads to an im-
provement of the headache, after an initial worsening for
1–2 weeks [17,19].
MOH has been suggested to include subgroups of
both simple and complex cases, where some of the latter
may show “dependency-like” behaviour [20-24].
Previous studies from our group have revealed that the
Severity of Dependence Scale (SDS) [25] can detectntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Table 1 The International Classification of Headache
Disorders, 2nd edition (ICHD - II) criteria for medication-
overuse headache [12-15]
Medication-overuse headache (MOH)
A. Headache present on ≥15 days/month
B. Regular overuse for >3 months of one or more drugs that can be
taken for acute and/or symptomatic treatment of headache
C. Headache has developed or markedly worsened during medication
overuse
For simple analgesics and for combination of acute medications the intake must
be 15 days or more per month, for triptans, ergotamins, opioids and combination
analgesics,10 days per month is enough to get the diagnosis of MOH.
Figure 1 Flowchart of study. Figure illustrates main time line with
the different phases with those mainly responsible for each phase
(lower part). Upper part shows time-points for Patients data
collection (2 week headache diaries (2w.diary) and interviews) as well
as timing of various moments for the Investigator group and GPs
with Brief Intervention training courses (BIC) for GPs and
intervention. BI, Brief intervention; BIC, Brief Intervention course; GP,
General practitioner.
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eral population [26,27].
Brief Intervention (BI) is a well-known approach to
identify and treat unhealthy alcohol use [28]. BI involves
the use of an identification tool followed by feedback to
the identified individual as being “at risk”. The final step
is to give information suggesting cutting down the use
of the particular substance to predefined “acceptable”
levels [28]. In primary care settings, there is now sub-
stantial evidence of the benefits and cost-effectiveness of
BI for alcohol and various other drugs [29-31].
We have previously reported data from an open, un-
controlled study of MOH in the general population,
which suggested that three out of four MOH subjects
managed to reduce their medication intake after just
short information [32]. Similar simple advice also works
in specialist care settings [33,34].
We have developed a BI for management of MOH.
Prior to the start-up of the pilot study we planned to in-
clude efficacy of the treatment versus controls as one
outcome. However, due to cost and expected low power
in a pilot study of reasonable size [35], we decided not
to include a control arm but rather focus on testing the
feasibility of the method observationally. It is strongly
recommended to use information (process, resources,
management and scientific) gathered in feasibility studies
to modify the research methodology to avoid practical
problems and potentially unexpected consequences of
embarking directly on a full scale study [36-38].
The aim of this feasibility study was thus to develop and
to test acceptability, practicability and logistics of using BI
for MOH in primary care in order to prepare and improve
a later full scale randomised controlled trial (RCT).
Method
Design
Observational feasibility study of an intervention for MOH
in a Norwegian general practice population (Figure 1).
Participants (GPs and patients) The study took place
in Oslo in 2010.The study population consisted of patients aged 18–50
on the patient lists of six GPs attending one continuous
medical education (CME) group who had accepted to
participate as a pilot group. Through the Norwegian GP
list-patient system, all citizens are listed with a GP
whether or not they have a reason to see their GP. A
short validated headache screening questionnaire includ-
ing questions about headache frequency, intensity (visual
analogue scale (VAS), migraine and medication use was
mailed to all 18–50 year old patients (N = 3575) on par-
ticipating GP`s lists. Names and addresses were ex-
tracted from GP lists using specially designed software
(Mediata Ltd, Tønsberg, Norway). All patients with self-
reported headache ≥15 days/month and headache
medication utilisation ≥10 days/month were invited to
participate. Insufficient language skills and complex pain
conditions were the only exclusion criteria. As this was a
pilot study, no reminders were sent out. Screening-
positive MOH patients invited into the intervention part
of the study only received information that this was a
study of headache care utilisation and that all participat-
ing patients would receive a headache interview and
clinical examination by a headache expert. In addition, it
was informed that some patients might be invited to a
consultation by their GP. Patients were, thus, not in-
formed that the focus was chronic headache and medi-
cation use or withdrawal.
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Brief Intervention course A one day course held by
two headache specialists (ESK and CL) including lec-
tures about emergency “red flag” headache, migraine
and tension-type headache and chronic headaches with
focus on MOH were given to the GPs. The content of
the BI course was partly based on feedback from a ran-
dom sample of 30 clinically active GPs at the Depart-
ment of General Practice at the University of Oslo,
regarding which headache-related problems they would
like more information on. A two-hour presentation of
the BI scheme with practical instructions exemplified by
role-play was given. The estimated time for an average
BI scheme was expected to be 9–10 minutes. All six GPsFigure 2 Flowchart of GPs brief intervention for MOH strategy.participated in a role-play of the BI after an initial dem-
onstration by the two headache specialists. The group
then discussed the BI scheme.
Brief Intervention scheme The BI strategy (Figure 2)
taught to the GPs consisted of:
1. The SDS questionnaire (Table 2) to identify patients
at risk for MOH, (SDS cut-off values: females: ≥5,
males ≥4). Inform patients above the cut-off that he
or she was identified as being at risk for MOH based
on Norwegian studies from the general population
[26,27]. Patients below cut-off values were given a
short version of the full BI.
Table 2 The five questions of the severity of dependence
scale (SDS) adapted for headache medication such that
“your drug” in the original scale was substituted for with
the relevant headache medication
1. Do you think your use of your headache medication was out of
control?
(Never/almost never=0, sometimes=1, often=2, always/nearly
always=3)
2. Did the prospect of missing a dose make you anxious or worried?
(Scoring as for question 1)
3. Did you worry about your use of your headache medication?
(Scoring as for question 1)
4. Did you wish you could stop?
(Scoring as for question 1)
5. How difficult did you find it to stop or go without your headache
medication?
(Not difficult=0, quite difficult=1, very difficult=2, impossible=3)
Each item is scored on a 4-point scale (0–3), and the total maximum score is 15.
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association between medication overuse and chronic
headache was given using a short standard
information folder developed by the study group.
3. Specific individualised information and advice
regarding reduction of acute headache medication
was discussed and given based on the individual SDS
score. The discussion aimed towards achieving a
decision by the patient that he/she would cut down
the offending medication, an agreement about how
the GP could support and a concrete plan.
The BI incorporated clear directive advice, but focus
was also on increasing patients’ insight and awareness
regarding overuse, using aspects from motivational
interviewing techniques. The primary aim of the BI was
to introduce behaviour change perspectives and discus-
sions in an empathic and collaborative manner. It was
designed to be relatively short and easily linked to the
SDS score. Bien et al. pointed out feedback on personal
risk and highlighted the following common motivational
elements of effective brief interventions; “Elements of an
effective BIs include Feedback on personal risk, emphasis
on Responsibility, clear Advice, a Menu of change op-
tions, clinician Empathy, and facilitation of patient Self-
efficacy.” [39].
Headache classification, interview and follow-up
Headache classification The headaches were classified
according to explicit diagnostic criteria of the ICHD-II
and it‘s relevant revisions [12-15].
Headache diary A validated headache diary [40] was used
in order to prospectively record data on headachefrequency, headache intensity (VAS) and medication use.
The completion of the diary for a two week period was re-
quired at baseline and at three months. A written instruc-
tion for the completion of the diary was mailed to
participants.
Three months follow-up All patients included in the
intervention part of the study were invited to a semi-
structured headache interview and clinical examination
by a GP specifically trained in headache interview tech-
niques (ESK).
Outcomes
To evaluate;
 Logistics of patient recruitment including extraction
of patients from GPs lists
 Practicality and contents of the BI course as
experience by the GPs
 The utility of the SDS and the BI procedure within
everyday clinical practice
 Responder rate, completion rate of screening
questionnaire and follow-up rate
 Acceptability and compliance of a headache diary
with only written instructions sent by mail prior to
the consultations
 Acceptability for the SDS and BI among patients
 The format of the three months interview
 Other issues that should be considered for a RCT as
identified by patients and/or GPs
The evaluation of the screening questionnaires, head-
ache diaries, BI, BI course and three months follow-up
from patients and GPs were not collected in a formal
qualitative way, but were given as individual written and
spoken feedback after the study was ended by mail,
e-mail or phone. Both patients and GPs were encouraged
to identify problems and give feedback during and after
the study. The feedback will only be presented as direct
quotes.
Patient-related outcomes were collected as a part of
testing the logistics, but were not a main outcome. The
primary and secondary outcomes for the full RCT have
been predefined in the study protocol and based on
international consensus independently of this feasibility
study [16,41,42]. The data from this pilot study will not
be pooled with data from the RCT.
Sample size
We found one CME group (six GPs) to be reasonable
to get appropriate information and feedback about the
GP perspectives of the methodology and logistics of
the study. According to the Norwegian Medical Associ-
ation, the average number of listed patients per GP is
Sample from GPs list 18-50 years
N= 3575
Study population
n=3412
Address error n= 160
Non-eligible n=3
Responders              
n=978
No response n=2429
Declined participation =5
Screening positive for MOH 
n=24
MOH invited into main study
n=24
MOH participants included
n=5
No response n=14
Declined participation n=1
Advanced comorbidity n=1
Insufficient language skills n =3
Lost to follow-up n=0
MOH participants received BI            
n=5
Lost to follow-up n=0
MOH participants followed up after BI                                   
n=5
Figure 3 Flowchart of the participating patients.
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patient per GP gives us an estimate of approximately 10
patients with MOH per GP. With an educational guess
of 40% responder rate without reminders that would be
24 MOH patients included.Statistics
Only descriptive statistics were used (SPSS version 20.0).
Registration of electronic data from the semi-structured
interviews was done by using Snap Survey (Snap Survey,
London, UK).
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The study was approved by the Regional Committee for
Medical Research Ethics and the Norwegian Social Sci-
ence Data Services (NSD). All participating patients and
GPs gave informed, written consent. All data were kept
anonymously.
Results
The participant, intervention and flow details are
summarised in the flow diagram depicted in Figure 3.
The response rate of the screening questionnaire was
29%.
Twenty-four persons screened positive for chronic
headache (≥15 days of headache/month) and 10 ≥medi-
cation days/month and were invited to the intervention
part of the study. Of these, five persons filled out the
headache diary for two weeks and were included. Five
out of six GPs completed a BI for MOH.
All five patients included, received BI, and none were
lost to follow-up.
Patients
The screening questionnaire was complete in over 98%
of received questionnaires.
Headache diaries were complete for all five patients at
both baseline and the three months follow-up.
The patients reported a high degree of acceptability of
the methodology and did not seem provoked by the
questions and comments about their medication intake.
Individual comments from patients:
“The screening questionnaire was self-explaining and
easy to understand, and the written instructions made
the headache diary easy to complete, but I think two
weeks fulfilling is the upper limit for completeness
when no physicians have told you why the diary is so
important!”
“I didn`t feel provoked or stressed when my GP asked
me about my medication use in this way, although this
is a touchy issue.”
“Individual feedback on medication use is very good;
all the information in the media does not concern me
as an individual.”
”For a long time I have considered my paracetamol
use to be too high but I didn’t know that it could
worsen my headache.”
“Nobody has ever told me about the risk of medication
overuse headache, the individual information was
very clear and relevant for me as a chronic pain
patient.”Table 3 shows patients characteristics at baseline and
three months follow-up. The mean SDS score for the
five patients included was 6. Of our five patients, four
had reduced medication days at follow up and four im-
proved regarding headache days.
General practitioners (GPs)
None of the physicians had previously received specific
training in the handling of MOH. The BI course was held
according to the predefined timeframe of eight hours.
The GPs reported the BI as being feasible to imple-
ment within a busy practice and that the BI represented
a new instrument for communication with these pa-
tients. During the introduction to the course, participat-
ing physicians were anxious about the topic of
medication overuse, especially regarding questions on
dependency, as possibly being of a very sensitive and
thereby provoking nature for the patients. This notion
disappeared during the course and this was further
strengthened by the feedback after the individual patient
intervention.
The time used on the BI scheme was reported between
7 and 12 minutes and well within the normal consult-
ation time.
Individual comments on the BI and the BI course:
“The BI course was informal and practice-relevant.”
”Management of chronic headache patients has always
been difficult, but seems easier after this course.”
“The SDS was a great tool to use in the consultation.”
“The SDS and BI strategies made it easy to talk to the
patient about her medication use.”
“The SDS was simple to use in practice and only
required about 1 minute of consultation time.”
“I had expected some negative feedback from my
patient bringing the subject of medication overuse into
the consultation, but the SDS and BI really helped us
both and made the communication quite easy.”
Three months follow-up
The time used for the three months follow-up was be-
tween 42 and 63 minutes for these five patients. The five
patients completed all the additional self-reported ques-
tionnaires. The time of completion ranged from 17 mi-
nutes to 44 minutes. One of the patients thought there
were too many questionnaires that explored the same
aspects of self-reported quality of life.
Using direct data entry (Snap Survey, UK) by the inter-
viewer during the interview itself was found to be
Table 3 Patient characteristics at baseline and after brief intervention (three months follow-up)
Patient Gender Age Overused medication at baseline Headache
days before BI
Headache
days before
BI (diary)+
Headache
days after BI
Headache
days after
BI (diary)+
Medication
days before BI
Medication
days before
BI (diary)+
Medication
days after BI
Medication
days after
BI (diary)+
Headache
diagnoses at
follow-up
1 Female 45 Paracetamol/Ibuprofen 30 30 30 30 30 30 30* 30 Cervicogenic
2 Male 27 Paracetamol/Ibuprofen 25 26 20 18 22 22 5 4 CTTH
3 Female 45 Paracetamol 30 30 18 16 30 30 2 2 CTTH
4 Female 29 Paracetamol/Ibuprofen 30 30 22 22 30 30 14 14 CTTH + migraine
5 Female 35 Combination analgesic
(Acetylsalicylic acid/Codeine/Caffeine)
18 18 14 14 18 18 12* 12 ETTH
Mean 36 27 27 21 20 26 26 13 12
BI; brief intervention, CTTH; chronic tension-type headache, ETTH; episodic tension-type headache.
+Headache days and medications days taken from 2 week headache diary.
*Two had completely terminated medication for 2 months but restarted before 3 months follow-up.
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of presenting their history. Completion of a structured
questionnaire on paper with subsequent data entry after
the interview was felt to be more optimal.
Software and data handling
The developed extracting software (from Mediata Ltd.)
used for capturing data from GPs lists performed well
and no problems were seen in generating patient lists.
Some minor technical problems with the data entry
using Snap Survey were seen and could be corrected.
Discussion
We have demonstrated that BI for MOH carried out by
minimally trained GPs seems feasible and acceptable by
both patients and GPs. The main focus was to test method-
ology and logistics, not patient related headache outcomes.
The responder rate was low (29%), and we included
fewer patients than expected. Before the study, we decided
that no reminders should be sent to patients because the
main aim of this study was to test methodology, accept-
ability and practicability. We also decided not to include a
control arm in the pilot trial, as this not was an efficacy
trial. The low number of MOH participants and lack of
control group may of course lead to selection bias and low
generalization, which suggests the need for increasing
individual responder rate and recruitment in a RCT to
secure external validity of our findings. The responder rate
found here was lower than in a previous study using the
same screening questionnaire [6]. The number of re-
minders used will always be a compromise between cost
and gain. In a study focusing on recruiting patients for an
intervention, representativity of the sample is important
but, providing recruitment is not biased between the study
arms in a later study, the percentage responder rate is of
less importance than for epidemiological studies. The
screening questionnaire was complete in over 98% of
received answers, so this seems to have been well under-
stood and accepted. Although the responder rate was low,
24 screening-positive MOH patients were in the range of
what we expected. Only 10/24 responded to the invitation
into the main study. There was no information in the invi-
tation letter about this being a medication withdrawal
study so a possibly negative attitude to this should not
have affected the recruitment. We screened all patients on
the GPs patient lists instead of relying only on the GPs
knowledge of their previous headache patients. Through
this screening we expected to reach possible chronic head-
ache patients who might not be known as such by their
GP.
The age range of patients (18–50 years of age) was
chosen in order to target the highest number of patients
with chronic headache, as the prevalence is lower in
younger people and older people have a higher frequencyof co-morbidities. We chose an upper age limit of 50 years
since data from the Norwegian prescription database [43]
indicate that there is an increase in the use of various
relevant drugs (notably anti-hypertensive and cardiovascu-
lar drugs) from 50 years of age onwards.
The headache diary and the written instructions were
reported to be acceptable from the patients actually
returning it, and recent studies using a similar headache
diary and written instructions before first consultation
found high usefulness, acceptability and comprehensibil-
ity of the diary as well as good compliance and com-
pleteness of data [44]. There was clear advice from the
patients not to use the headache diary for periods over
two weeks since this might reduce compliance. This
period may seem too short for infrequent forms of head-
ache, but in our sample of chronic sufferers this should
not be a problem.
The evaluation of GPs and patients were not collected
in a formal qualitative way, but were given as individual
written and spoken feedback after the study was ended.
Given the fact that the feedback was quite similar with
no major differences regarding the GPs experience of
their own patients as being simple or complex, and with
no differences between patients managing medication
withdrawal or not, we conclude, although few included
patients that the BI for MOH seems feasible.
A Danish study has shown that feasibility, acceptability
and implementation of screening and brief intervention
programs for alcohol overuse in primary care may cause
more problems than they solve for some GPs because it
might be problematic to incorporate a in a busy daily
practice [45]. The feedback from our pilot group of GPs
indicated that the SDS and BI were feasible and consid-
ered clinically relevant. Our estimated time of 9–10 mi-
nutes matched the 7–12 minutes the GPs used on the BI
scheme, and all GPs found this easy to do within normal
consultation time, even though two of the GPs didn`t
know their MOH patients in advance as these patients
had never consulted their GP for headache before. 7–
12 minutes is well within the normal Norwegian GP
consultation time of about 15–20 minutes, in addition
we might expect the GPs using less time when more fa-
miliar with the BI scheme.
There is still much discussion as to whether MOH
represents dependency [20-24]. Being fully aware of this
and the potentially problems with stigmatizing these pa-
tients, we used the SDS score, not as an attempt to de-
fine dependency, but rather as an aid for the GPs to
focus on individual risk of medication overuse [26,27].
The GPs did not use the SDS as a universal screening
and case finding instrument, it was only used in the BI
consultation as an educational tool to give personal feed-
back. This personal feedback on a risk score is what
probably makes the BI scheme more effective than just
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anxious about the topic of medication overuse, especially
regarding questions on dependency, as possibly being of
a very sensitive and thereby provoking nature for the pa-
tients. This worry was reduced after the study but sug-
gests the importance of further focus on the experiences
of the GPs in the planned RCT with a formal qualitative
part.
We had tested the Snap Survey data collection form
many times and in many different settings ahead of this
study, but still found new errors during the interviews
and when reading the data into SPSS. This was not due
to the Snap Survey software itself but was a consequence
of how the questions and response alternatives were for-
mulated. Such problems may in many cases not have
been detected without a pilot trial.
The three months follow-up interviews and additional
questionnaires were all performed as planned. The pa-
tients reported the questionnaires to be acceptable, one
patient though there were too many questions about
quality of life and headache-related quality of life
[47-49]. However, these instruments have very wide-
spread use and acknowledged validity for assessing qual-
ity of life and headache related quality of life and impact
and their use is therefore important in order to compare
outcomes with other studies.
The patient data support the importance of perform-
ing an RCT to assess efficacy of the BI. Two of the pa-
tients had completely terminated medication for two
months but relapsed before three months follow-up be-
cause none of them had received appropriate information
from the BI scheme about the importance of staying medi-
cation free until the three months follow up.
As a consequence of the nature of this feasibility study
we will use previous results from a study from Akershus
University Hospital [32] as the basis for the power calcu-
lation and sample size required in the RCT. Another
reason is that results of pilot studies can potentially mis-
lead sample size or power calculations in full scale RCTs
because results may already be biased because of the
limited sample size in most pilot studies [35]. None of
the data from this study will be used in the RCT to avoid
any bias.
In summary, findings suggesting changes in the planned
method for the RCT were the need for at least one, and
probably two reminders for both the screening question-
naire and the invitation into the intervention part of the
study. In addition, since our contacts with the GPs in the
pilot study suggested that more than three patients per
GP would be difficult to achieve for practical reasons, we
must increase the number of GPs included in an RCT.
The patients need to receive appropriate information
about the importance of staying medication free until the
three months follow-up.We have already published the study protocol with
most of these modifications incorporated [42], but
nevertheless, we regard the specific methods to be of
separate interest, and this feasibility study underlines the
importance of doing a proper feasibility and/or pilot
study to avoid too many unexpected flaws in a full RCT.
Conclusion
In this pilot study, BI for MOH seems feasible and ac-
ceptable by both patients and GPs. We intend to test the
efficacy of BI for MOH in a double-blind pragmatic
cluster-RCT since this is a simple intervention with a
potential to reach many suffering patients at the lowest
effective health care level (GP).
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